相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Susanna V. Ulahannan et al.
CANCER INVESTIGATION (2011)
Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
Richard H. de Boer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway
Grzegorz Korpanty et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2010)
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non Small-Cell Lung Cancer
Giorgio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non-Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
Glenwood D. Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
Roy S. Herbst et al.
LANCET ONCOLOGY (2010)
Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
George N. Naumov et al.
CLINICAL CANCER RESEARCH (2009)
Toxicity of Targeted Therapy in Non-Small-Cell Lung Cancer Management
Serena Ricciardi et al.
CLINICAL LUNG CANCER (2009)
An overview of small-molecule inhibitors of VEGFR signaling
S. Percy Ivy et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
Nathan A. Pennell et al.
ONCOLOGIST (2009)
Investigational Agents in the Management of Non-Small Cell Lung Cancer
Nathan A. Pennell et al.
CURRENT ONCOLOGY REPORTS (2009)
Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
John V. Heymach et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies
Petros Nikolinakos et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim et al.
LANCET (2008)
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer
John V. Heymach et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epidemiology of lung cancer - ACCP evidence-based clinical practice guidelines (2nd edition)
Anthony J. Alberg et al.
CHEST (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Toxicities of antiangiogenic therapy in non-small-cell lung cancer
Roy S. Herbst
CLINICAL LUNG CANCER (2006)
Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood
RM Bremnes et al.
LUNG CANCER (2006)
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy
F. Ciardiello et al.
ANNALS OF ONCOLOGY (2006)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
FV Fossella et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
FA Shepherd et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
